MART-1 reactive CD8+ lymphocytes

{
  "id": "MLC-T-ONC-015012",
  "term": "MART-1 reactive CD8+ lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor-associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity.",
  "synonyms": [
    "MART-1 reactive CD8-positive T lymphocytes",
    "MART 1-reactive PBL"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mart-1-reactive-cd8-plus-lymphocytes/"
}